Your browser doesn't support javascript.
loading
Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder.
Yan, Tingjian; Greene, Mallik; Chang, Eunice; Broder, Michael S; Touya, Maëlys; Munday, Jennifer; Hartry, Ann.
Afiliação
  • Yan T; Health Services Research, Partnership for Health Analytic Research, LLC, 280 S Beverly Dr, Beverly Hills, CA 90212, USA.
  • Greene M; Health Economics and Outcomes Research, Otsuka Pharmaceutical Development & Commercialization, Inc., 508 Carnegie Center, Princeton, NJ 08540, USA.
  • Chang E; Health Services Research, Partnership for Health Analytic Research, LLC, 280 S Beverly Dr, Beverly Hills, CA 90212, USA.
  • Broder MS; Health Services Research, Partnership for Health Analytic Research, LLC, 280 S Beverly Dr, Beverly Hills, CA 90212, USA.
  • Touya M; Health Economics and Outcomes Research, Lundbeck, 6 Parkway North, Deerfield, IL 60015, USA.
  • Munday J; Health Services Research, Partnership for Health Analytic Research, LLC, 280 S Beverly Dr, Beverly Hills, CA 90212, USA.
  • Hartry A; Health Economics and Outcomes Research, Lundbeck, 6 Parkway North, Deerfield, IL 60015, USA.
J Comp Eff Res ; 8(4): 217-227, 2019 03.
Article em En | MEDLINE | ID: mdl-30556736
ABSTRACT

AIM:

To examine hospitalization risk factors in antipsychotic-treated patients with schizophrenia, bipolar I disorder (BD-I) or major depressive disorder (MDD). PATIENTS &

METHODS:

Using Truven Health MarketScan® Commercial, Medicaid and Medicare Supplemental data (01/01/2012-06/30/2016), logistic regression models were performed to identify risk factors for both psychiatric and all-cause hospitalization in three separate analyses.

RESULTS:

Significant risk factors included prior hospitalization (schizophrenia odds ratio [95% CI] 2.83 [2.50-3.21; psychiatric]; 2.58 [2.31-2.87; all-cause]; BD-I 2.42 [2.23-2.63]; 2.09 [1.96-2.23]; MDD 2.81 [2.49-3.16]; 2.21 [2.03-2.40]), previous antipsychotic treatment (schizophrenia 1.71 [1.52-1.93]; 1.31 [1.18-1.46]; BD-I 1.33 [1.23-1.44]; 1.22 [1.14-1.30]; MDD 1.31 (1.11-1.54); 1.17 (1.04-1.32) and substance abuse (schizophrenia 1.42 [1.27-1.60]; 1.37 [1.23-1.53]; BD-I 1.72 [1.58-1.86]; 1.61 [1.50-1.72]; MDD 1.90 [1.68-2.15] and 1.55 [1.41-1.71]).

CONCLUSION:

Prior hospitalization, previous antipsychotic treatment and substance abuse were associated with increased hospitalization risk in schizophrenia, BD-I or MDD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Transtorno Bipolar / Transtorno Depressivo Maior / Hospitalização Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esquizofrenia / Antipsicóticos / Transtorno Bipolar / Transtorno Depressivo Maior / Hospitalização Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article